To start or to complete? – Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India

References

• World Health Organization. Global tuberculosis report 2018. Geneva, Switzerland: WHO; 2018.
   Google Scholar
• World Health Organization. TB-HIV: WHO factsheet 2018. Geneva, Switzerland: WHO; 2018.
   Google Scholar
• Joint United Nations Programme on HIV/AIDS. UNAIDS - India: overview [Internet]. 2017 [cited 2019 Oct 4]. Available from: https://www.unaids.org/en/regionscountries/countries/india
   Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva, Switzerland: WHO; 2016.
   Google Scholar
• World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, Switzerland: WHO; 2018.
   Google Scholar
• World Health Organization. Implementing the end TB strategy: the essentials. Geneva, Switzerland: WHO. 2017;1–14
   Google Scholar
• United Nations. Sustainable development knowledge platform: sustainable developmental goal 3 [Internet]. 2018 [cited 2018 Sep 7]. Available from: https://sustainabledevelopment.un.org/sdg3
   Google Scholar
• TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–822.
   PubMed Web of Science ®Google Scholar
• INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV/AIDS. Global HIV & AIDS statistics — 2018 fact sheet [Internet]. 2018 [cited 2018 Sep 6]. Available from: http://www.unaids.org/en/resources/fact-sheet
   Google Scholar
• Gupta A, Wood R, Kaplan R, et al. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. Polis MA, editor. PLoS One. 2012;7:e34156.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Rice B, Brown AE, et al. Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV. 2015;2:e243–e251.
   PubMed Web of Science ®Google Scholar
• Zunza M, Gray DM, Young T, et al. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev. 2017;8:CD006418.
   PubMed Web of Science ®Google Scholar
• Charan J, Goyal JP, Reljic T, et al. Isoniazid for the prevention of tuberculosis in HIV-infected children. Pediatr Infect Dis J. 2018;37:773–780.
   Web of Science ®Google Scholar
• Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1:CD000171.
   Web of Science ®Google Scholar
• Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441–1448.
   PubMed Web of Science ®Google Scholar
• Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631–636.
   PubMed Web of Science ®Google Scholar
• Yirdaw KD, Jerene D, Gashu Z, et al. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. McBryde ES, editor. PLoS One. 2014;9:e104557.
   PubMed Web of Science ®Google Scholar
• Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690.
   PubMed Web of Science ®Google Scholar
• Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Heal. 2017;5:e1080–e1089.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva, Switzerland: WHO; 2004.
   Google Scholar
• Sah SK, Sahu SK, Lamichhane B, et al. Dotting the Three I’s for collaborative TB-HIV activities: evaluation of a pilot programme in Kathmandu, Nepal. Public Heal Action. 2016;6:169–175.
   Web of Science ®Google Scholar
• Ayele HT, van Mourik MSM, Bonten MJM. Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2016;20:1342–1347.
   PubMed Web of Science ®Google Scholar
• Takarinda KC, Choto RC, Harries AD, et al. Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. Public Heal Action. 2017;7:55–60.
   PubMed Web of Science ®Google Scholar
• Ayele AA, Asrade Atnafie S, Balcha DD, et al. Self-reported adherence and associated factors to isoniazid preventive therapy for latent tuberculosis among people living with HIV/AIDS at health centers in Gondar town, North West Ethiopia. Patient Prefer Adherence. 2017;11:743–749.
   Web of Science ®Google Scholar
• Ousley J, Soe KP, Kyaw NTT, et al. IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence. Public Heal Action. 2018;8:20–24.
   Web of Science ®Google Scholar
• Little KM, Khundi M, Barnes GL, et al. Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi. Int J Tuberc Lung Dis. 2018;22:371–377.
   PubMed Web of Science ®Google Scholar
• Dhungana GP, Thekkur P, Chinnakali P, et al. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. BMJ Open. 2019;9:e029058.
   Web of Science ®Google Scholar
• United Nations. Meetings coverage and press releases: world leaders reaffirm commitment to end tuberculosis by 2030, as General Assembly adopts declaration outlining actions for increased financing, treatment access [Internet]. 2018. [cited 2019 Jun 25]. Available from: https://www.un.org/press/en/2018/ga12067.doc.htm
   Google Scholar
• Ministry of Health and Family Welfare, Government of India. Guidelines on prevention and management of TB in PLHIV at ART centres. New Delhi, India: MoHFW, GoI; 2016.
   Google Scholar
• Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. London, UK: SAGE Publications; 2011.
   Google Scholar
• Population of Karnataka - Karnataka PCS Free Notes [Internet]. [ cited 2018 Sep 6]. Available from: https://karnataka.pscnotes.com/geography-karnataka/population-of-karnataka/
   Google Scholar
• Office of the Registrar General & Census Commissioner Ministry of Home Affairs, Government of India. The States of India By Land Area - WorldAtlas.com [Internet]. 2011 [cited 2018 Sep 6]. Available from: https://www.worldatlas.com/articles/what-are-the-states-of-india.html
   Google Scholar
• National AIDS Control Organization & ICMR-National Institute of Medical Statistics. HIV Estimations 2017: Technical Report. New Delhi; 2018.
   Google Scholar
• Karnataka State AIDS Prevention Society. Karnataka State AIDS Prevention Society - Services [Internet]. [ cited 2019 Jun 27]. Available from: https://ksaps.gov.in/services_art.html.
   Google Scholar
• Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people Living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. Murray M, editor. PLoS Med. 2011;8:e1000391.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. Geneva: Switzerland; 2000.
   Google Scholar
• Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163–170.
   PubMedGoogle Scholar
• Attride-Stirling J. Thematic networks: an analytic tool for qualitative research. Qual Res. 2001;1:385–405.
   Google Scholar
• Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Heal Care. 2007;19:349–357.
   PubMed Web of Science ®Google Scholar
• Brand RA. Editorial: standards of reporting: the CONSORT, QUORUM, and STROBE Guidelines. Clin Orthop Relat Res. 2009;467:1393–1394.
   PubMed Web of Science ®Google Scholar
• Teklay G, Teklu T, Legesse B, et al. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016;16:840.
   PubMed Web of Science ®Google Scholar
• Hodes R, Price I, Bungane N, et al. How front-line healthcare workers respond to stock-outs of essential medicines in the Eastern Cape Province of South Africa. South Afr Med J. 2017;107:738.
   Web of Science ®Google Scholar
• Trap B, Musoke R, Kirunda A, et al. Article 2: longitudinal study assessing the one-year effects of supervision performance assessment and recognition strategy (SPARS) to improve medicines management in Uganda health facilities. J Pharm Policy Pract. 2018;11:15.
   Google Scholar
• Poku RA, Owusu AY, Mullen PD, et al. HIV antiretroviral medication stock-outs in Ghana: contributors and consequences. African J AIDS Res. 2017;16:231–239.
   PubMed Web of Science ®Google Scholar
• Zakumumpa H, Kiweewa FM, Khuluza F, et al. “The number of clients is increasing but the supplies are reducing”: provider strategies for responding to chronic antiretroviral (ARV) medicines stock-outs in resource-limited settings: a qualitative study from Uganda. BMC Health Serv Res. 2019;19:312.
   Web of Science ®Google Scholar
• Hamada Y, Ford N, Schenkel K, et al. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review. Int J Tuberc Lung Dis. 2018;22:1422–1428.
   PubMed Web of Science ®Google Scholar
• Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus Isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001–1011.
   PubMed Web of Science ®Google Scholar
• World Health Organization. LTBI care: a mobile app to support programmatic management of LTBI [Internet]. WHO. World Health Organization; 2018 [cited 2019 Jul 2]. Available from: https://www.who.int/tb/areas-of-work/preventive-care/ltbi/ltbi_app/en/.
   Google Scholar